-
Product Insights
NewOrnithine Decarboxylase – Drugs In Development, 2024
The Ornithine Decarboxylase pipeline drugs market research report outlays comprehensive information on the Ornithine Decarboxylase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Genetic Disorders, Non Malignant Disorders, and Metabolic Disorders which include indications of Neuroblastoma, Gastric Cancer, Familial Adenomatous Polyposis, Adenomas, and Type 1 Diabetes (Juvenile Diabetes). It also reviews key players involved in Ornithine...
-
Product Insights
NewN Myc Proto Oncogene Protein – Drugs In Development, 2024
The N Myc Proto Oncogene Protein pipeline drugs market research report outlays comprehensive information on the N Myc Proto Oncogene Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Neuroblastoma, and Medulloblastoma. It also reviews key players involved in N Myc Proto Oncogene Protein targeted therapeutics development with respective active and dormant...
-
Product Insights
NewProcollagen Proline Dioxygenase – Drugs In Development, 2024
The Procollagen Proline Dioxygenase pipeline drugs market research report outlays comprehensive information on the Procollagen Proline Dioxygenase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Hematological Disorders, Toxicology, and Oncology which include indications of Anemia in Chronic Kidney Disease (Renal Anemia), Anemia, Chemotherapy Induced Anemia, and Neuroblastoma. It also reviews key players involved in Procollagen Proline Dioxygenase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Evofosfamide in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Evofosfamide in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Evofosfamide in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRX-100 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRX-100 in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRX-100 in Melanoma Drug Details: CRX-100 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRX-100 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRX-100 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRX-100 in Non-Small Cell Lung Cancer Drug Details: CRX-100...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RP-1664 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-1664 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RP-1664 in Solid Tumor Drug Details: RP-1664 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensartinib Hydrochloride in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ensartinib Hydrochloride in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ensartinib Hydrochloride in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pidnarulex in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pidnarulex in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pidnarulex in Prostate Cancer Drug Details: Pidnarulex is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diakine-DK210 (EGFR) in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diakine-DK210 (EGFR) in Head And Neck Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diakine-DK210 (EGFR) in Head And Neck Cancer Drug...